China Accepts Sac TMT Lung Cancer Filing
China-source update: Kelun-Biotech’s Chinese-language newsroom listed on 28 October that CDE accepted a seventh sac-TMT indication filing for first-line PD-L1-negative, EGFR/ALK-negative nonsquamous NSCLC with pembrolizumab. The underlying Phase III OptiTROP-Lung06 data were reported earlier,…
